Displaying 561 - 580 of 1554
Agilent Technologies, Inc., In the Matter of
Agilent Technologies, Inc. and Varian, Inc., two leading global suppliers of high-performance scientific measurement instruments, have agreed to sell three of their product lines in order to proceed with their proposed $1.5 billion merger. According to the FTC’s complaint, Agilent’s acquisition of Varian would have reduced competition for three types of scientific measurement instruments. To resolve these competitive concerns, the parties have agreed to sell assets related to the manufacture and sale of: 1) Micro Gas Chromatography (Micro GC) instruments; 2) Triple Quadrupole Gas Chromatography-Mass Spectrometry (3Q GC-MS) instruments; and 3) Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) instruments.
FTC Requires Casino Operators Penn National Gaming, Inc. and Pinnacle Entertainment, Inc. to Divest Assets in Three Midwestern Cities as a Condition of Merger
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules (July 2018)
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules (August 2018)
FTC Approves Final Order Requiring Grifols S.A. to Divest Assets as Condition of Acquiring Biotest US Corporation
Grifols, S.A., and Grifols Shared Services North America, Inc., In the Matter of
The FTC required global healthcare company Grifols S.A. to divest blood plasma collection centers in three U.S. cities, among other conditions, as part of a settlement resolving charges that Grifols’ acquisition of Florida-based Biotest US Corporation is anticompetitive and violates federal antitrust law. The complaint alleges that, as proposed, the acquisition would harm competition in the markets for collection of human blood plasma in Lincoln, Nebraska, Augusta, Georgia, and Youngstown, Ohio. Grifols and Biotest US are the only companies that operate plasma collection centers in these cities, and, without a remedy, the merger would result in a merger-to-monopoly in these cities. Under the terms of the proposed settlement, Grifols will divest its plasma collection centers in these three cities to KedPlasma, which is a subsidiary of Kedrion Biopharma Inc., a leading manufacturer of protein products and the fifth-largest producer of plasma proteins worldwide.
The complaint also alleges that, absent a remedy, the acquisition would harm the U.S. market for hepatitis B immune globulin, or HBIG, a plasma-derived injectable medicine that provides hepatitis B antibodies for preventing hepatitis B infections. When Grifols announced the proposed acquisition in December 2017, Biotest US owned 41 percent of ADMA Biologics, Inc., which has the largest share in the U.S. market for HBIG and competes with Grifols and one other supplier. Biotest US has recently transferred its ownership share in ADMA to The Biotest Divestiture Trust, the parent company of Biotest US. Because Grifols is only seeking to acquire Biotest US and not its parent, Grifols will not acquire any ownership interest in ADMA under the proposed acquisition. Under the proposed consent agreement, Grifols is prohibited, without prior notification, from acquiring any ownership interest in ADMA or obtaining any rights to nominate or obtain representation on the ADMA Board of Directors.
FTC Approves Two Applications from Alimentation Couche-Tard Inc. for Sale of Eight Retail Fuel Stations in Minnesota and Wisconsin
Alimentation Couche-Tard and CrossAmerica Partners, In the Matter of
Statement by FTC Bureau of Competition Director Bruce Hoffman on the Court Granting a Preliminary Injunction in the Tronox/Cristal Matter
Simulating Hospital Merger Simulations
FTC Approves Alimentation Couche-Tard Inc.’s Application for Sale of Two Retail Fuel Stations in Minnesota
FTC Approves Final Order Imposing Conditions on Construction Company CRH plc
CRH plc, In the Matter of
FTC Requires Grifols S.A. to Divest Assets as Condition of Acquiring Biotest US Corporation
Wilhelm Wilhelmsen/Drew Marine, In the Matter of
The FTC issued an administrative complaint charging that Wilhelmsen Maritime Services’ proposed $400 million acquisition of Drew Marine Group would violate the antitrust laws by significantly reducing competition in an important market for marine water treatment chemicals and services used by global fleets. Marine water treatment chemicals and services are used by tankers, container ships, bulk carriers, cruise ships, and military support vessels to maintain critical on-board equipment. The FTC alleges that if consummated, the merger would result in a company controlling at least 60 percent of the global marine water treatment chemical and service market, leaving only inferior alternatives for global fleets. The FTC also authorized staff to seek in federal court a temporary restraining order and a preliminary injunction to prevent the parties from consummating the merger, and to maintain the status quo pending the administrative proceeding.
The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes
Displaying 561 - 580 of 1554